Patheon to make tough cuts at U.K. facility; Charles River CEO downplays asset transfer deals;

 @NesaNFierce: Monkey see, monkey ... don't. MPI Research is getting lots of flack from the USDA and an animal rights group over animal mistreatment. | Follow @NesaNFierce

> Struggling Canadian CMO Patheon will need to eliminate more than 90 jobs and downsize production at its facility in Swindon, U.K., after failing to sell it. More

> Charles River CEO James Foster downplays his interest in asset transfer deals, saying they don't make "rational sense," especially if the potential deals are outside his company's vicinity. News

> While pharma and clinical jobs in the Americas fell 10%, they went up 25% in Europe, according Ed Silverman of Pharmabiz. Article

> INC Research has expanded its business relationship with Medidata Solutions by attaining three new accreditations for Medidata's clinical cloud platform. Release

And Finally… ACRO India sounds off to FierceCRO about a Pharmabiz report that says ACRO India helped spur the video documentation of clinical trials in the country. But while the umbrella organization denies ever making any comments to Pharmabiz, it neither confirmed nor denied videotaping reports. Story

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.